Skip to main content


Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells

Fig. 6

Targeted Gal-1 inhibition by OTX008 reduces oncogenic properties of Gal-1. a. A dosage of 50 μM OTX008 (OTX) was sufficient to inhibit MHCC97L cell proliferation rate. b. The same dosage was applied to MHCC97L cells to significantly reduce the number of colonies formed in a soft agar assay. c. The migratory and invasive abilities were reduced in MHCC97L cells after treatment. d. Tumor growth was monitored and significantly showed the inhibition of growth when mice were treated with sorafenib, OTX008 and the combined treatment of OTX008 and sorafenib, compared to the vehicle control. e. Combined treatment of sorafenib and OTX008 significantly attenuated end tumor volume and dimension. f. Representative images showing H&E and immunohistochemical staining of Gal-1 and Ki67 on tumors of different experimental groups are shown. g. Summary of the signaling of Gal-1 in HCC. *P < 0.05, ****P < 0.0001, P < 0.05 is considered statistically significant

Back to article page